-transparent.png){kind=logo}
Anemia is one of the serious complications of chronic renal failure, therapy with recombinant human erythropoietin (r-HuEPO) can correct such anemia officiently. For most patients, the initial dose of r-HuEPO is 100U/kg, by intravenously or subcutaneous, three times a week. After 6 weeks of treatment, Hb could increase to 100g/L, and Hct to above 0.33-0.35. Then 500/kg 3 time a week can be used as maintaining dose. 4 patients need maintaining dose of 150U/kg, for pulmonary infection, poor nutrition, and poor iron supply. Therefore, during the treatment, iron folie acid and Vit B12 should be applied sufficiently and treat the infection effectively with the increasing of Hb and Hct, 2/3 of the patients have hypertension which can be controlled with medication. If there is thrombosis in the dialyzer, the dose of heparin should be increased. The patients on r-HuEPO should be dialysised sufficiently to prevent hyperkalemia.
Y Jiang, and
P Liu, and
E J Wang
January 1990,
Annual review of medicine,
Y Jiang, and
P Liu, and
E J Wang
June 1991,
International journal of hematology,
Y Jiang, and
P Liu, and
E J Wang
October 1990,
The American journal of medicine,
Y Jiang, and
P Liu, and
E J Wang
January 1988,
Deutsche medizinische Wochenschrift (1946),
Y Jiang, and
P Liu, and
E J Wang
July 1987,
The New England journal of medicine,
Y Jiang, and
P Liu, and
E J Wang
May 1988,
International journal of cell cloning,
Y Jiang, and
P Liu, and
E J Wang
September 1992,
The Canadian veterinary journal = La revue veterinaire canadienne,
Y Jiang, and
P Liu, and
E J Wang
January 1996,
Nephron,
Y Jiang, and
P Liu, and
E J Wang
July 1989,
The New England journal of medicine,
Y Jiang, and
P Liu, and
E J Wang
April 1991,
Transplantation proceedings,
